综合的表型和蛋白质查识别了顶级阿尔茨海默病治疗点
Gregory A Cary1, Qianjin Li2, Jesse C Wiley3
1The Jackson Laboratory for Mammalian Genetics, Bar Harbor ME.
bioRxiv : the preprint server for biology
|November 24, 2025
概括
这项研究开发了一个新的查平台,以验证潜在的阿尔茨海默病 (AD) 治疗点. 确定了五个关键目标 (Ap2a2,Pdhb,Pdha1,Dlat,Psmc3) 进行进一步开发以对抗AD.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 蛋白质组学是指蛋白质组学.
背景情况:
- 阿尔茨海默病 (AD) 是一种复杂的神经退行性疾病,已确定了许多潜在的治疗点.
- 有效的优先考虑这些目标仍然是AD药物发现的重大挑战.
研究的目的:
- 应用一个综合性查框架来评估AD的候选治疗目标.
- 使用可扩展的平台验证功能性目标,该平台将系统级的AD风险数据与实验验证相结合.
主要方法:
- 使用了小鼠BV2微质细胞系与稳定的Psen2敲击.
- 进行了siRNA介导的扰动,随后进行了细胞表型分析和定量蛋白质组学.
- 综合蛋白质组分析以确定颠覆AD相关分子模式的扰动.
主要成果:
- 在29个候选细胞中,有25个目标显著改变了细胞表型,在Psen2淘汰细胞中增强了效果.
- 确定了五个关键目标 - - Ap2a2,Pdhb,Pdha1,Dlat和Psmc3 - - 影响了表型和蛋白质反应.
- 证明了几种扰动可以逆转与AD相关的分子模式.
结论:
- 在阿尔茨海默病研究中建立了一个可扩展的功能目标验证平台.
- 成功确定和验证了阿尔茨海默病的五个有前途的治疗点.
- ESSJ TREAT-AD中心将优先考虑为这些验证的目标进一步开发资源.
更多相关视频
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
27.9K
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
8.2K
相关概念视频
01:22Alzheimer's Disease: Treatment
772
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
772
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K